Potential effect and mechanism of action of topical chamomile (Matricaria chammomila L.) oil on migraine headache: A medical hypothesis

Medical Hypotheses

Volumn 83, Issue 5, 2014, Pages 566-569

  Zargaran, Arman ^a,b   Borhani Haghighi, Afshin ^c   Faridi, Pouya ^a   Daneshamouz, Saeid ^d   Kordafshari, Gholamreza ^e   Mohagheghzadeh, Abdolali ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

APIGENIN; BISABOLOL; CHAMAZULENE; CHAMOMILE; ESSENTIAL OIL; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PROSTAGLANDIN E2; SESAME SEED OIL; ANTIINFLAMMATORY AGENT; AZULENE DERIVATIVE; PLANT EXTRACT; VEGETABLE OIL;

ANALGESIA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; DRUG ADMINISTRATION ROUTE; DRUG EFFECT; DRUG FORMULARY; DRUG FORMULATION; DRUG MECHANISM; ENZYME INHIBITION; ENZYME SYNTHESIS; HERBAL MEDICINE; HUMAN; INFLAMMATION; MACROPHAGE ACTIVATION; MATRICARIA CHAMOMILLA; MIGRAINE; NEUROPROTECTION; PROTEIN EXPRESSION; ANIMAL; CELL LINE; CHEMISTRY; DRUG EFFECTS; MACROPHAGE; METABOLISM; MIGRAINE DISORDERS; MOUSE; PHYTOTHERAPY; PROCEDURES; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; APIGENIN; AZULENES; CELL LINE; CHAMOMILE; HUMANS; MACROPHAGES; MICE; MIGRAINE DISORDERS; PAIN MANAGEMENT; PHYTOTHERAPY; PLANT EXTRACTS; PLANT OILS; SESAME OIL;

EID: 84908257258     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2014.08.023     Document Type: Article

References (55)

1. Ayatollahi S.M.T., Sahebi L., Borhani-Haghighi A. Epidemiologic and clinical characteristics of migraine and tension-type headaches among hospitals staffs of Shiraz (Iran). Acta Med Iran 2009, 47(2):115-120.
2. Min Y.W., Lee J.H., Min B.H., Lee J.H., Kim J.J., Chung C.S., et al. Clinical predictors for migraine in patients presenting with nausea and/or vomiting. J Neurogastroenterol Motil 2013, 19(4):516-520.
3. The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 2013, 33(9):629-808. Headache Classification Committee of the International Headache Society (IHS).
4. Andlin-Sobocki P., Jonsson B., Wittchen H.U., Olesen J. Cost of disorders of the brain in Europe. Eur J Neurol 2005, 12(Suppl 1):1-27.
5. Hoffmann J., Goadsby P.J. Emerging Targets in Migraine. CNS Drugs 2014, 28(1):11-17.
6. Tfelt-Hansen P.C. Triptans and ergot alkaloids in the acute treatment of migraine: similarities and differences. Expert Rev Neurother 2013, 13(9):961-963.
7. Lipton R.B., Serrano D., Nicholson R.A., Buse D.C., Runken M.C., Reed M.L. Impact of NSAID and triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache 2013, 53(10):1548-1563.
8. Lipton R.B., Stewart W.F. Acute migraine therapy: do doctors understand what patients with migraine want from therapy?. Headache 1999, 39:20-26.
9. Zargaran A., Zarshenas M.M., Karimi A., Yarmohammadi H., Borhani-Haghighi A. Management of stroke as described by Ibn Sina (Avicenna) in the Canon of Medicine. Int J Cardiol 2013, 169(4):233-237.
10. Zargaran A., Zarshenas M.M., Mehdizadeh A., Mohagheghzadeh A. Management of tremor in medieval Persia. J Hist Neurosci 2013, 22(1):53-61.
11. Zargaran A., Fazelzadeh A., Mohagheghzadeh A. Surgeons and surgery from ancient Persia (5000 years of surgical history). World J Surg 2013, 37(8):2002-2004.
12. Golzari S.E., Khan Z.H., Ghabili K., Hosseinzadeh H., Soleimanpour H., Azarfarin R., et al. Contributions of medieval Islamic physicians to the history of tracheostomy. Anesth Analg 2013, 116(5):1123-1132.
13. Zargaran A., Zarshenas M.M., Ahmadi S.A., Vessal K. Haly Abbas (949-982 AD). J Neurol 2013, 260(8):2196-2197.
14. Pierce M.W. Transdermal delivery of sumatriptan for the treatment of acute migraine. Neurotherapeutics 2010, 7(2):159-163.
15. Pfaffenrath V., Fenzl E., Bregman D., Färkkila M. Intranasal ketorolac tromethamine (SPRIX(R)) containing 6% of lidocaine (ROX-828) for acute treatment of migraine: safety and efficacy data from a phase II clinical trial. Cephalalgia 2012, 32(10):766-777.
16. Tepper S.J., Chen S., Reidenbach F., Rapoport A.M. Intranasal zolmitriptan for the treatment of acute migraine. Headache 2013, 53(Suppl 2):62-71.
17. Schulman E.A. Transdermal sumatriptan for acute treatment of migraineurs with baseline nausea. Headache 2012, 52(2):204-212.
18. Borhani Haghighi A., Motazedian S., Rezaii R. Therapeutic potentials of menthol in migraine headache: possible mechanisms of action. Med Hypotheses 2007, 69(2):455.
19. Borhani Haghighi A., Motazedian S., Rezaii R., Mohammadi F., Salarian L., Pourmokhtari M., et al. Cutaneous application of menthol 10% solution as an abortive treatment of migraine without aura: a randomized, double-blind, placebo-controlled, crossed-over study. Int J Clin Pract 2010, 64(4):451-456.
20. Gorji A. Khaleghi Ghadiri M. History of headache in medieval Persian medicine. Lancet Neurol 2002, 1(8):510-515.
21. Zarshenas M.M., Petramfar P., Firoozabadi A., Moein M.R., Mohagheghzadeh A. Types of headache and those remedies in traditional Persian medicine. Pharmacogn Rev 2013, 7(13):17-26.
22. Abokrysha N. Ibn Sina (Avicenna) on pathogenesis of migraine compared with the recent theories. Headache 2009, 49(6):923-927.
23. Avicenna. Canon of Medicine. Tehran, Iran: Soroosh Press; 1025/1998.
24. Heravi MA. Al-Abnieh an Haghaiegh al Advieh. Corrected by Bahmaniar A. Tehran: Tehran University; 1992.
25. Tonekaboni H. Tohfat ol momenin. Tehran, Iran: Nashre shahr Press; 1670/2007.
26. Aghili Shirazi MH. Makhzan-ol-Advieh [Storehouse of Medicaments]. Tehran: Intisharat va Amoozesh Enghelab Islami Press; 1771/1992.
27. Rhazes. Al Havi [Liber Continent]. Trans. into Persian by S Afsharipour. Tehran: The Academy of Medical Sciences; Tenth century/2005.
28. Aghili Shirazi SMH. Qarabadin-e-Kabir. Tehran, Iran: Ostad Allah Qoli khan Qajar; 1772/1855.
29. Heravi MG. Qarabadin-e-Salehi. Tehran, Iran: Dar-ol-khalafeh [Litograph in Persian]; 1765.
30. Sawalha A.F., Sweileh W.M., Zyoud S.H., Jabi S.W. Self-therapy practices among university students in Palestine: focus on herbal remedies. Complement Ther Med 2008, 16(6):343-349.
31. Maday E., Tyihak E., Szöke E. Occurrence of formaldehyde in intact plants, micropropagated plants and hairy root cultures of chamomile (Matricaria recutita L.). Plant Growth Regul 2000, 30:105-110.
32. Bhowmik D., Chiranjib, Jaiswal J., Tripathi K.K., Kumar K.P.S. Recent aspect of drug therapy of migraine patients. Arch Appl Sci Res 2010, 2(1):113-124.
33. Hamedi A., Zarshenas M.M., Sohrabpour M., Zargaran A. Herbal medicinal oils in traditional Persian medicine. Pharm Biol 2013, 51(9):1208-1218.
34. Abolhassanzadeh Z. Formulation and clinical evaluation of two traditional topical remedies from Syrian Rue and Saatar on osteoarthritic pain [PhD thesis]. Iran: Shiraz University of Medical Sciences; 2014.
35. Ho T.W., Edvinsson L., Goadsby P.J. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 2010, 6(10):573-582.
36. Silberstein S.D. Migraine pathophysiology and its clinical implications. Cephalalgia 2004, 24(Suppl. 2):2-7.
37. Dodick D., Silberstein S. Central sensitization theory of migraine: clinical implications. Headache 2006, 46(Suppl. 4):S182-191.
38. Panconesi A. Serotonin and migraine: a reconsideration of the central theory. J Headache Pain 2008, 9(5):267-276.
39. Barbanti P., Egeo G., Aurilia C., Fofi L., Della-Morte D. Drugs targeting nitric oxide synthase for migraine treatment. Expert Opin Investig Drugs 2014, 23(8):1141-1148.
40. Olesen J. The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache. Pharmacol Ther 2008, 120(2):157-171.
41. Bhaskaran N., Shukla S., Srivastava J.K., Gupta S. Chamomile: an anti-inflammatory agent inhibits inducible nitric oxide synthase expression by blocking RelA/p65 activity. Int J Mol Med 2010, 26(6):935-940.
42. Ansari M, Rafiee K, Emamgholipour S, Fallah MS. Migraine: molecular basis and herbal medicine. In: Chen KS, editor, Advanced topics in neurological disorders. InTech. ISBN: 978-953-51-0303-5. Available from: . http://www.intechopen.com/books/advanced-topics-in-neurological-disorders/migraine-molecular-basis-and-herbal-medicine.
43. Srivastava J.K., Pandey M., Gupta S. Chamomile, a novel and selective COX-2 inhibitor with anti-inflammatory activity. Life Sci 2009, 85(19-20):663-669.
44. Srivastava J.K., Shankar E., Gupta S. Chamomile: a herbal medicine of the past with bright future. Mol Med Rep 2010, 3(6):895-901.
45. Ross S.M. An integrative approach to eczema (atopic dermatitis). Holist Nurs Pract 2003, 17(1):56-62.
46. Charousaei F., Dabirian A., Mojab F. Using chamomile solution or a 1% topical hydrocortisone ointment in the management of peristomal skin lesions in colostomy patients: results of a controlled clinical study. Ostomy Wound Manage 2011, 57(5):28-36.
47. Drummond E.M., Harbourne N., Marete E., Martyn D., Jacquier J., O'Riordan D., et al. Inhibition of proinflammatory biomarkers in THP1 macrophages by polyphenols derived from chamomile, meadowsweet and willow bark. Phytother Res 2013, 27(4):588-594.
48. Stanimirovic D.B., Friedman A. Pathophysiology of the neurovascular unit: disease cause or consequence?. J Cereb Blood Flow Metab 2012, 32(7):1207-1221.
49. Yilmaz N., Karaali K., Ozdem S., Turkay M., Unal A., Dora B. Elevated S100B and neuron specific enolase levels in patients with migraine-without aura: evidence for neurodegeneration?. Cell Mol Neurobiol 2011, 31(4):579-585.
50. Chandrashekhar V.M., Ranpariya V.L., Ganapaty S., Parashar A., Muchandi A.A. Neuroprotective activity of Matricaria recutita Linn against global model of ischemia in rats. J Ethnopharmacol 2010, 127(3):645-651.
51. Asanuma M., Nishibayashi-Asanuma S., Miyazaki I., Kohno M., Ogawa N. Neuroprotective effects of non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals. J Neurochem 2001, 76(6):1895-1904.
52. Bradley Morris J. Food, industrial, nutraceutical, and pharmaceutical uses of sesame genetic resources. Trends in new crops and new uses 2002, ASHS Press, Alexandria, VA. J. Janick, A. Whipkey (Eds.).
53. Phitak T., Pothacharoen P., Settakorn J., Poompimol W., Caterson B., Kongtawelert P. Chondroprotective and anti-inflammatory effects of sesamin. Phytochemistry 2012, 80:77-88.
54. Nekuzad N., Ashke Torab T., Mojab F., Alavi-Majd H., Azadeh P., Ehtejab G. Effect of external use of sesame oil in the prevention of chemotherapy-induced phlebitis. Iran J Pharm Res 2012, 11(4):1065-1071.
55. Zahmatkash M., Vafaeenasab M.R. Comparing analgesic effects of a topical herbal mixed medicine with salicylate in patients with knee osteoarthritis. Pak J Biol Sci 2011, 14(13):715-719.